Literature DB >> 33411113

Association between serum potassium levels and adverse outcomes in chronic kidney disease: the Fukushima CKD cohort study.

Kenichi Tanaka1,2, Hirotaka Saito3, Tsuyoshi Iwasaki3, Akira Oda3, Shuhei Watanabe3, Makoto Kanno3,4, Hiroshi Kimura3, Michio Shimabukuro4,5, Koichi Asahi4,6, Tsuyoshi Watanabe4, Junichiro J Kazama3,4.   

Abstract

BACKGROUND: Serum potassium disorders, commonly observed in chronic kidney disease (CKD), are reportedly associated with higher mortality, but their impact on renal outcomes is still controversial.
METHODS: The present study used the longitudinal data of the Fukushima CKD cohort study to investigate the relationships between hypokalemia and hyperkalemia and adverse outcomes such as renal outcomes and all-cause mortality in Japanese patients with non-dialysis-dependent CKD. The study involved 1330 CKD patients followed-up for 2.8 years. The primary endpoint of the present study was a kidney event, defined as a combination of doubling of baseline serum creatinine and end-stage kidney disease.
RESULTS: Hyperkalemia (≥ 5.0 mmol/L) was noted in 10.6% and hypokalemia (< 4.0 mmol/L) in 16.4% of the study population. Significant U-shaped associations were observed between potassium levels and both kidney events and all-cause mortality on univariate Cox regression analyses. After adjustment for covariates, both hypokalemia and hyperkalemia were significantly associated with an increased risk of kidney events, with the lowest risk at a serum potassium of 4.0-4.4 mmol/L. Compared with a reference level of 4.0-4.4 mmol/L, the adjusted hazard ratio for kidney events was 2.49 (1.33-4.66) for serum potassium < 4.0 mmol/L, 1.72 (1.00-2.96) for 4.5-4.9 mmol/L, and 2.16 (1.15-4.06) for ≥ 5.0 mmol/L. There was no significant association between serum potassium levels and mortality after multivariate adjustment.
CONCLUSION: Hypokalemia and hyperkalemia were associated with an increased risk of CKD progression, but not with mortality in Japanese patients with non-dialysis-dependent CKD.

Entities:  

Keywords:  Chronic kidney disease; End-stage renal disease; Hyperkalemia; Hypokalemia; Mortality; Potassium

Year:  2021        PMID: 33411113     DOI: 10.1007/s10157-020-02010-7

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  2 in total

1.  Blood pressure control in chronic kidney disease according to underlying renal disease: the Fukushima CKD cohort.

Authors:  Aya Nakajima; Kenichi Tanaka; Hirotaka Saito; Tsuyoshi Iwasaki; Akira Oda; Makoto Kanno; Michio Shimabukuro; Koichi Asahi; Tsuyoshi Watanabe; Junichiro James Kazama
Journal:  Clin Exp Nephrol       Date:  2019-12-26       Impact factor: 2.801

Review 2.  The influence of potassium on blood pressure.

Authors:  R L Tannen
Journal:  Kidney Int Suppl       Date:  1987-10       Impact factor: 10.545

  2 in total
  3 in total

1.  Association of Polypharmacy with Kidney Disease Progression in Adults with CKD.

Authors:  Hiroshi Kimura; Kenichi Tanaka; Hirotaka Saito; Tsuyoshi Iwasaki; Akira Oda; Shuhei Watanabe; Makoto Kanno; Michio Shimabukuro; Koichi Asahi; Tsuyoshi Watanabe; Junichiro James Kazama
Journal:  Clin J Am Soc Nephrol       Date:  2021-11-15       Impact factor: 8.237

2.  Association between Serum Inorganic Phosphorus Levels and Adverse Outcomes in Chronic Kidney Disease: The Fukushima CKD Cohort Study.

Authors:  Akira Oda; Kenichi Tanaka; Hirotaka Saito; Tsuyoshi Iwasaki; Shuhei Watanabe; Hiroshi Kimura; Sakumi Kazama; Michio Shimabukuro; Koichi Asahi; Tsuyoshi Watanabe; Junichiro James Kazama
Journal:  Intern Med       Date:  2021-11-20       Impact factor: 1.282

Review 3.  Chronic Hyperkaliemia in Chronic Kidney Disease: An Old Concern with New Answers.

Authors:  Silvio Borrelli; Ida Matarazzo; Eugenio Lembo; Laura Peccarino; Claudia Annoiato; Maria Rosaria Scognamiglio; Andrea Foderini; Chiara Ruotolo; Aldo Franculli; Federica Capozzi; Pavlo Yavorskiy; Fatme Merheb; Michele Provenzano; Gaetano La Manna; Luca De Nicola; Roberto Minutolo; Carlo Garofalo
Journal:  Int J Mol Sci       Date:  2022-06-07       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.